General MedicationsORALGeneric
FARYDAK
PANOBINOSTAT LACTATE
Standard Dose
EQ 15MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview FARYDAK is listed in Drugs@FDA under application 205353 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient PANOBINOSTAT LACTATE Form and strength CAPSULE;ORAL - EQ 15MG BASE Sponsor SECURA Submission history Latest submission status date: 2016-06-06 00:00:00.
Structured Monograph
Clinical summary
Approval overview FARYDAK is listed in Drugs@FDA under application 205353 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient PANOBINOSTAT LACTATE Form and strength CAPSULE;ORAL - EQ 15MG BASE Sponsor SECURA Submission history Latest submission status date: 2016-06-06 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.